Albert Rosenfeld - Net Worth and Insider Trading

Albert Rosenfeld Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Albert Rosenfeld owns 1 companies in total, including Regenerx Biopharmaceuticals Inc (RGRX) .

Click here to see the complete history of Albert Rosenfeld’s form 4 insider trades.

Insider Ownership Summary of Albert Rosenfeld

Ticker Comapny Transaction Date Type of Owner
RGRX Regenerx Biopharmaceuticals Inc 2005-04-01 director

Albert Rosenfeld Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Albert Rosenfeld Ownership Network

Ownership Network List of Albert Rosenfeld

No Data

Ownership Network Relation of Albert Rosenfeld

Insider Network Chart

Albert Rosenfeld Owned Company Details

What does Regenerx Biopharmaceuticals Inc do?

Who are the key executives at Regenerx Biopharmaceuticals Inc?

Albert Rosenfeld is the director of Regenerx Biopharmaceuticals Inc. Other key executives at Regenerx Biopharmaceuticals Inc include other: Member of 10% owner group Aptafin S P A , 10 percent owner Spa Essetifin , and 10 percent owner Francesca Cavazza .

Regenerx Biopharmaceuticals Inc (RGRX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Regenerx Biopharmaceuticals Inc (RGRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Regenerx Biopharmaceuticals Inc (RGRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Regenerx Biopharmaceuticals Inc (RGRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Regenerx Biopharmaceuticals Inc Insider Transactions

No Available Data

Albert Rosenfeld Mailing Address

Above is the net worth, insider trading, and ownership report for Albert Rosenfeld. Currently GuruFocus does not have mailing address information for Albert Rosenfeld.

Discussions on Albert Rosenfeld

No discussions yet.